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Oral Contraception Woes: Idiosyncratic Drug Induced Liver Injury 
Abdul Aleem, MD and She-Yan Wong, MD
Department of Gastroenterology and Hepatology, Lehigh Valley Health Network, Allentown, PA
BACKGROUND 
•  Idiosyncratic drug-induced liver 
injury (DILI) is one of the most 
common causes of acute liver 
failure in the United States. 
•  The clinical manifestations of DILI 
can range from asymptomatic liver 
test abnormalities to prolonged 
jaundice or overt acute liver failure. 
•  Oral contraceptives (OCCs) are 
associated with DILI; however 
modern OCCs have not been known 
to cause liver transaminase 
elevations at rates any higher than 
placebo. 
•  We report a case of a patient who 
presents with jaundice and elevated 
transaminases one week after 
starting OCCs.
CASE PRESENTATION
•  A 29-year old female of Indian origin 
presented to her primary care physician’s 
office with complaints of fatigue and pruritus. 
•  Laboratory workup revealed elevated liver 
function test results (Table 1). 
•  History was negative for any coexisting 
medical disorders, alcohol or illicit drug use. 
•  Family history was positive for cholestasis of 
pregnancy in her mother and sister. 
•  The patient reported taking OCCs (norethin-
drone acetate and ethinyl estradiol) one week 
prior to the onset of her symptoms. 
•  Further evaluation showed a negative serologic 
workup for chronic liver disease including 
viral hepatitis and autoimmune disease. 
•  Imaging was normal. 
•  She underwent a liver biopsy that showed 
minimal active hepatocellular damage and 
mild cholestasis. (Images 1 and 2)
•  The patient’s symptoms and jaundice were 
attributed to OCCs. 
•  Her OCCs were discontinued resulting in 
significant improvement in her symptoms and 
complete normalization of her liver function 
tests (Table 2).
TABLE 1: LIVER FUNCTION TESTS ON OCCS
Component Values Units
Total Bilirubin 3.6 3.5 mg/dl
ALP 102 92 U/L
AST 152 257 U/L
ALT 237 378 U/L
TABLE 2: TREND OF LIVER FUNCTION TESTS  
AFTER DISCONTINUING THE OCCS
Time Week 1 Week 2 Week 3 Week 5 Units
Total Bilirubin 4.6 5.2 3.2 0.6 mg/dl
ALP 104 127 151 71 U/L
AST 358 100 63 16 U/L
ALT 621 320 140 20 U/L
Images 1and 2: Histopathology showing 
minimal active hepatocellular damage, mild 
cholestasis and focal minimal portal fibrosis.
DISCUSSION
•  The pathophysiology of OCCs 
associated DILI has been related  
to bile salt transporter mutations 
and is similar to that of cholestasis  
of pregnancy. 
•  Interestingly, this patient’s family 
history was positive for cholestasis 
of pregnancy. 
•  Our patient has never been pregnant, 
but has plans to become pregnant 
in the future. 
•  She was advised that she is at 
increased risk of developing 
cholestasis of pregnancy. 
•  Our case report illustrates the 
importance of obtaining a thorough 
history as it has the implications of 
the cause of DILI as well as 
guidance for the future.
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